Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
NTLA

NTLA - Intellia Therapeutics Inc Stock Price, Fair Value and News

$13.82-1.01 (-6.81%)
Market Closed

26/100

NTLA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

26/100

NTLA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$11.7

Target 3M

$13.37

Target 6M

$12.44

NTLA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NTLA Price Action

Last 7 days

-1.5%

Last 30 days

51.2%

Last 90 days

12.6%

Trailing 12 Months

38.1%

NTLA RSI Chart

NTLA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

NTLA Valuation

Market Cap

1.6B

Price/Earnings (Trailing)

-3.59

Price/Sales (Trailing)

27.83

EV/EBITDA

-13.16

Price/Free Cashflow

-3.88

NTLA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$11.7

Target 3M

$13.37

Target 6M

$12.44

NTLA Fundamentals

NTLA Revenue

Revenue (TTM)

57.5M

Rev. Growth (Yr)

51.27%

Rev. Growth (Qtr)

-3.25%

NTLA Earnings

Earnings (TTM)

-445.8M

Earnings Growth (Yr)

25.34%

Earnings Growth (Qtr)

-0.07%

NTLA Profitability

EBT Margin

-117.41%

Return on Equity

-59.57%

Return on Assets

-48.18%

Free Cashflow Yield

-25.78%

NTLA Investor Care

Shares Dilution (1Y)

13.73%

Diluted EPS (TTM)

-4.26

NTLA Alerts

  • 1 major insider buys and 2 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202545.6M52.9M57.5M0
202441.7M47.1M52.5M57.9M
202353.5M53.0M51.8M36.3M
202237.9M45.3M51.4M52.1M
202151.5M41.8M26.8M33.1M
202045.6M50.7M62.3M58.0M
201933.4M36.8M40.0M43.1M
201827.4M29.1M29.2M30.4M
201720.9M22.6M25.1M26.1M
20166.5M9.4M12.5M16.5M
20150006.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Intellia Therapeutics Inc

NTLA
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas. It also focus on programs comprising hemophilia A and hemophilia B; ex vivo pipeline including NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Further, the company has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; and SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. Additionally, it has license and coloration agreement with Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. to develop optimally engineered natural killer cell therapies to cure patients with cancer; and Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEintelliatx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES598

Intellia Therapeutics Inc Frequently Asked Questions

NTLA is the stock ticker symbol of Intellia Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Intellia Therapeutics Inc is 1.6 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check NTLA's fair value in chart for subscribers.

The fair value guage provides a quick view whether NTLA is over valued or under valued. Whether Intellia Therapeutics Inc is cheap or expensive depends on the assumptions which impact Intellia Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NTLA.

As of Wed Jan 28 2026, NTLA's PE ratio (Price to Earnings) is -3.59 and Price to Sales (PS) ratio is 27.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NTLA PE ratio will change depending on the future growth rate expectations of investors.